Anatara Lifesciences Ltd Cash Flow-to-Debt Ratio
Anatara Lifesciences Ltd cash flow-to-debt ratio. Anatara Lifesciences Ltd (ANR) has a Cash Flow-to-Debt Ratio of -2.24x as of June 2025, meaning its operating cash flow of AU$-1.37 Million could theoretically repay -2% of its total liabilities (AU$612.42K) in one year. Check Anatara Lifesciences Ltd (ANR) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Anatara Lifesciences Ltd (2013–2025)
Cash flow-to-debt ratio of Anatara Lifesciences Ltd from 2013 to 2025. Historical debt coverage capacity for Anatara Lifesciences Ltd across 13 annual periods. Check ANR cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Anatara Lifesciences Ltd Cash Flow-to-Debt Ratio by Year (2013–2025)
Anatara Lifesciences Ltd cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Anatara Lifesciences Ltd. For the full cash flow conversion analysis, see Anatara Lifesciences Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.71x | AU$-2.27 Million | AU$612.42K | ▲ +8.7% |
| 2024 | -4.07x | AU$-1.25 Million | AU$306.85K | ▲ +10.9% |
| 2023 | -4.56x | AU$-2.26 Million | AU$494.83K | ▲ +17.6% |
| 2022 | -5.54x | AU$-2.23 Million | AU$403.35K | ▼ -31.1% |
| 2021 | -4.22x | AU$-2.10 Million | AU$496.67K | ▲ +24.5% |
| 2020 | -5.60x | AU$-2.72 Million | AU$486.96K | ▼ -16.7% |
| 2019 | -4.79x | AU$-2.24 Million | AU$466.76K | ▼ -77.1% |
| 2018 | -2.71x | AU$-3.32 Million | AU$1.22 Million | ▲ +72.2% |
| 2017 | -9.74x | AU$-2.88 Million | AU$295.44K | ▼ -1445.1% |
| 2016 | -0.63x | AU$-280.37K | AU$444.62K | ▲ +95.2% |
| 2015 | -13.09x | AU$-1.92 Million | AU$146.98K | ▼ -366.2% |
| 2014 | -2.81x | AU$-639.27K | AU$227.62K | ▼ -459.4% |
| 2013 | -0.50x | AU$-177.22K | AU$352.96K | — |